TY - JOUR
T1 - Generic and Respiratory-Specific Quality of Life in Non-Hospitalized Patients with COVID-19
AU - Meys, Roy
AU - Delbressine, Jeannet M.
AU - Goertz, Yvonne M. J.
AU - Vaes, Anouk W.
AU - Machado, Felipe V. C.
AU - Van Herck, Maarten
AU - Burtin, Chris
AU - Posthuma, Rein
AU - Spaetgens, Bart
AU - Franssen, Frits M. E.
AU - Spies, Yvonne
AU - Vijlbrief, Herman
AU - Van't Hul, Alex J.
AU - Janssen, Daisy J. A.
AU - Spruit, Martijn A.
AU - Houben-Wilke, Sarah
PY - 2020/12
Y1 - 2020/12
N2 - The impact of coronavirus disease 2019 (COVID-19) on quality of life appears to be highly underestimated, especially in patients who have not been admitted to the hospital. Therefore, our aim was to assess respiratory-specific quality of life in addition to generic quality of life in former patients with confirmed/suspected COVID-19 who have never been admitted to the hospital. Members of an online Belgian social support group for patients with confirmed/suspected COVID-19 with persistent complaints, completed an online survey. The five-level EQ-5D (EQ-5D-5L) and the Clinical COPD Questionnaire (CCQ) were used to assess generic and respiratory-specific quality of life, respectively. Data of 210 non-hospitalized patients (88% women, 45 +/- 11 years, 79 +/- 17 days after symptom onset) were included in the analyses. Mean EQ-5D index and visual analogue scale (EQ-VAS) score was 0.62 +/- 0.19 and 50.71 +/- 18.87, respectively, with 40% of the patients demonstrating an EQ-5D index that was below the fifth percentile of normative values, indicating poor generic quality of life. The mean CCQ score was 2.01 +/- 0.98 points, while 123 respondents (59%) had a total score >= 1.9 points, indicating poor respiratory-specific quality of life. The correlation between EQ-5D index score/EQ-VAS score and CCQ total score was moderate (r = -0.524 and r = -0.374; both p <0.001). In conclusion, both generic and respiratory-specific quality of life are affected in non-hospitalized patients with COVID-19, approximately three months after the onset of symptoms. The combined use of the EQ-5D and the CCQ could identify the broad impact of COVID-19 on quality of life.
AB - The impact of coronavirus disease 2019 (COVID-19) on quality of life appears to be highly underestimated, especially in patients who have not been admitted to the hospital. Therefore, our aim was to assess respiratory-specific quality of life in addition to generic quality of life in former patients with confirmed/suspected COVID-19 who have never been admitted to the hospital. Members of an online Belgian social support group for patients with confirmed/suspected COVID-19 with persistent complaints, completed an online survey. The five-level EQ-5D (EQ-5D-5L) and the Clinical COPD Questionnaire (CCQ) were used to assess generic and respiratory-specific quality of life, respectively. Data of 210 non-hospitalized patients (88% women, 45 +/- 11 years, 79 +/- 17 days after symptom onset) were included in the analyses. Mean EQ-5D index and visual analogue scale (EQ-VAS) score was 0.62 +/- 0.19 and 50.71 +/- 18.87, respectively, with 40% of the patients demonstrating an EQ-5D index that was below the fifth percentile of normative values, indicating poor generic quality of life. The mean CCQ score was 2.01 +/- 0.98 points, while 123 respondents (59%) had a total score >= 1.9 points, indicating poor respiratory-specific quality of life. The correlation between EQ-5D index score/EQ-VAS score and CCQ total score was moderate (r = -0.524 and r = -0.374; both p <0.001). In conclusion, both generic and respiratory-specific quality of life are affected in non-hospitalized patients with COVID-19, approximately three months after the onset of symptoms. The combined use of the EQ-5D and the CCQ could identify the broad impact of COVID-19 on quality of life.
KW - COVID-19
KW - quality of life
KW - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
KW - QUESTIONNAIRE
U2 - 10.3390/jcm9123993
DO - 10.3390/jcm9123993
M3 - Article
C2 - 33317214
VL - 9
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
SN - 2077-0383
IS - 12
M1 - 3993
ER -